Beovu Lawsuits for Vision Loss, Blindness, and Other Serious Eye Problems
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Beovu, prescribed for the treatment of neovascular (wet) age-related macular degeneration (AMD) since 2019, has been associated with vision loss and blindness due to occlusive retinal vasculitis, retinal artery occlusion, and intraocular inflammation. Beginning in January 2021, Beovu lawsuits have been filed against Novartis, the manufacturer of Beovu, alleging this drug company failed to adequately warn doctors and patients about these Beovu side effects.
In fact, the first two of these Beovu vision loss lawsuits were for clients of our law firm.
Beovu eye-related side effects include:
- Vision Loss
- Blindness
- Occlusive Retinal Vasculitis
- Retinal Vasculitis
- Retinal Artery Occlusion
- Intraocular Inflammation
- Eye Inflammation
- Endophthalmitis
- Retinal Detachment
- Uveitis
For more information about this still-developing Beovu safety issue, we suggest you view our Up-to-Date Timeline for Beovu page.
Our law firm is investigating possible Beovu lawsuits for patients who have suffered vision loss or blindness after their Beovu injections.
Free Beovu Case Evaluation
We encourage you to submit a Beovu Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, nor some other lawyer – about your case based on his many years of experience.
Most Recent Article About Beovu
Beovu Drug Label Revised December 2021 Was Issued in Europe, But Not in the US
A “new” Beovu drug label which was revised in December 2021 sets forth some additional information about the vision-related Beovu side effects intraocular inflammation, retinal vasculitis, and retinal vascular occlusion. We point out, however, that there was no similar 2021 Beovu label change issued by Novartis in the US.
To read more of this article, click below:
From this Drug Safety Update, “Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals”, issued January 18, 2022, by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), we get the following:
New information on [the Beovu adverse events retinal vasculitis and retinal vascular occlusion], including risk factors and possible mechanism, was considered in a recent European safety review and ophthalmologists were informed of the new recommendations in a letter in November 2021. The product information of [Beovu (brolucizumab)] will also be updated to reflect this information.
In the so-called “Dear Doctor” letter about Beovu that Novartis UK sent on November 2, 2021, to healthcare professionals in the UK there are these two important sections:
- “Risk factors identified”; and,
- “Immune‐mediated event”.
We expect that a similar Beovu drug label change, and a possible associated Beovu “Dear Doctor” letter, will be issued by Novartis here in the US soon.
Be assured we will continue to monitor the drug safety regulatory sector for further developments regarding Beovu vision loss side effects such as intraocular inflammation, retinal vasculitis, and retinal vascular occlusion.
For more information about Beovu causing vision loss and blindness due to occlusive retinal vasculitis, retinal artery occlusion, and intraocular inflammation, see our Beovu Side Effects page on our DrugInjuryLaw.com website.
[Read article in full at original source]Earlier articles about Beovu by attorney Tom Lamb on the Side Effects Blog:
- Beovu: Rates of Intraocular Inflammation and Retinal Vascular Occlusion
- Novartis Stops 3 Beovu Clinical Trials in May 2021, Wants a Beovu Label Change
- Beovu Lawsuits are Filed As Individual Cases; 3 Reasons to Contact Us
- Beovu Side Effects and Beovu Lawsuits for Patients Complicate Future for Beovu
- Beovu: What Comes Next for This Troubled Novartis AMD Drug?
- Beovu Retinal Vasculitis Made Worse by a Later Lucentis Treatment: Case Report
- Beovu-related Retinal Vasculitis and Beovu Vision Loss Cases
- Beovu Injections Side Effects: Novartis Points Out Risk Factors and Possible Causes in November 2020 Report
- Beovu Legal Cases: Compensation for Eye Problems from Beovu Use
- Beovu-associated Endophthalmitis is “New” for Beovu Eye Drug Safety Issue of Vision Loss
- Beovu Use Continues Despite Ongoing Beovu-associated Inflammation Investigation
- Safety of Beovu Update: Study Results Announcement by Novartis and Beovu Label Change in Europe
- After Two Injections of Beovu, Retinal Vasculitis With Vision Loss
- Beovu | July 2020 | Current Findings For Occlusive Vasculitis And Vision Loss
- Beovu: External Safety Review Committee Findings Lead To New Vision-Related Side Effects Warnings
- New Beovu Warnings About Risks Of Retinal Vasculitis And Retinal Vascular Occlusion
- Beovu Vision Loss And Retinal Vasculitis Cases May Lead To New Warnings
- Beovu Warning For Retinal Vasculitis: Is Current Drug Label Sufficient “As Is”?
- Beovu Warning: Retinal Vasculitis Which Can Lead To Blindness / Vision Loss